PPARalpha agonist5 is an orally active, selective partial agonist of PPARalpha with an EC50 of 3 nM. It reduces lipid accumulation and upregulates PPARalpha target genes, exhibiting anti-hepatic steatosis properties. Additionally, PPARalpha agonist5 demonstrates significant lipid-lowering and glucose-lowering effects through partial PPARgamma agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC50 of 79.1 µM. It has favorable safety and is applicable in the study of dyslipidemia in type 2 diabetes.
Target:
Phosphatase|||PPAR
* VAT and and shipping costs not included. Errors and price changes excepted
